Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2791 results

Clinical Trials / Feb 20, 2026

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Clinical Trials / Mar 11, 2026

Secukinumab Open Label Roll-over Extension Protocol
Clinical Trials / Apr 06, 2026

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Clinical Trials / May 05, 2026

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Event calendar
Caring for the mental health and wellbeing of our people
Press release / May 21, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report…
Expected currency impact
Novartis financial data
Press release / May 17, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12…

‹ Previous page
1
…
15
16
17
18
19
20
21
…
280
› Next page